Ventavis

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
30-11-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
30-11-2023

Viambatanisho vya kazi:

iloprost

Inapatikana kutoka:

Bayer AG

ATC kanuni:

B01AC11

INN (Jina la Kimataifa):

iloprost

Kundi la matibabu:

Antithrombotic agents

Eneo la matibabu:

Hypertension, Pulmonary

Matibabu dalili:

Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.

Bidhaa muhtasari:

Revision: 30

Idhini hali ya:

Authorised

Idhini ya tarehe:

2003-09-15

Taarifa za kipeperushi

                                42
B. PACKAGE LEAFLET
43
PACKAGE LEAFLET: INFORMATION FOR THE USER
VENTAVIS 10 MICROGRAM/ML NEBULISER SOLUTION
iloprost
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ventavis is and what it is used for
2.
What you need to know before you use Ventavis
3.
How to use Ventavis
4.
Possible side effects
5.
How to store Ventavis
6.
Contents of the pack and other information
1.
WHAT VENTAVIS IS AND WHAT IT IS USED FOR
WHAT VENTAVIS IS
The active substance of Ventavis is iloprost. It imitates a natural
substance in the body called
prostacyclin. Ventavis inhibits unwanted blocking or narrowing of
blood vessels and allows more
blood to flow through the vessels.
WHAT VENTAVIS IS USED FOR
Ventavis is used to treat moderate cases of primary pulmonary
hypertension (PPH) in adult patients.
PPH is a category of pulmonary hypertension where the cause of the
high blood pressure is not known.
This is a condition where blood pressure is too high in the blood
vessels between the heart and the
lungs.
Ventavis is used to improve exercise capacity (the ability to carry
out physical activity) and symptoms.
HOW VENTAVIS WORKS
Breathing in the mist carries Ventavis to the lungs, where it can work
most effectively in the artery
between heart and lungs. Improved blood flow leads to a better supply
of oxygen to the body and
reduced strain on the heart.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE VENTAVIS
DO NOT USE VENTAVIS
•
IF YOU ARE ALLERGIC
to iloprost or any of the other ingredients of this medicine (listed
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
_ _
_ _
_ _
_ _
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ventavis 10 microgram/ml nebuliser solution
Ventavis 20 microgram/ml nebuliser solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ventavis 10 microgram/ml nebuliser solution
1 ml solution contains 10 microgram iloprost (as iloprost trometamol).
Each ampoule with 1 ml solution contains 10 microgram iloprost.
Each ampoule with 2 ml solution contains 20 microgram iloprost.
Ventavis 20 microgram/ml nebuliser solution
1 ml solution contains 20 microgram iloprost (as iloprost trometamol).
Each ampoule with 1 ml solution contains 20 microgram iloprost.
Excipient with known effect
•
Ventavis 10 microgram/ml:
Each ml contains 0.81 mg ethanol 96% (equivalent to 0.75 mg ethanol)
•
Ventavis 20 microgram/ml:
Each ml contains 1.62 mg ethanol 96% (equivalent to 1.50 mg ethanol).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nebuliser solution.
Ventavis 10 microgram/ml nebuliser solution
Clear, colourless solution.
Ventavis 20 microgram/ml nebuliser solution
Clear, colourless to slightly yellowish solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of adult patients with primary pulmonary hypertension,
classified as NYHA functional
class III, to improve exercise capacity and symptoms.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
DRUG PRODUCT
SUITABLE INHALATION DEVICE (NEBULISER) TO BE USED
Ventavis 10 microgram/ml
Breelib
I-Neb AAD
Venta-Neb
Ventavis 20 microgram/ml
Breelib
I-Neb AAD
Ventavis should only be initiated and monitored by a physician
experienced in the treatment of
pulmonary hypertension.
3
Posology
_Dose per inhalation session _
At initiation of Ventavis treatment the first inhaled dose should be
2.5 microgram iloprost as delivered
at the mouthpiece of the nebuliser. If this dose is well tolerated,
dosing should be increased to
5 microgram iloprost and maintained at that dose. In case of poor
tolerability of the 5 microgram dose,
the dose should be reduced to 2.5 micr
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kireno 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 07-02-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 30-11-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 30-11-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 30-11-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 30-11-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 07-02-2014

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati